Deciphera Pharmaceuticals (Nasdaq:DCPH) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

DCPH Aperçu des actions

A biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.

A propos de l'entreprise

DCPH analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	2/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Se négocie à 85.1% en dessous de notre estimation de sa juste valeur

Les revenus devraient augmenter 23.56% par an

Analyse des risques

Cours de l'action très volatil au cours des 3 derniers mois

Les actionnaires ont été dilués au cours de l'année écoulée

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Deciphera Pharmaceuticals, Inc. Concurrents

Zai Lab

NasdaqGM:ZLAB

US$2.3b

Veracyte

NasdaqGM:VCYT

US$2.6b

Twist Bioscience

NasdaqGS:TWST

US$2.7b

ACADIA Pharmaceuticals

NasdaqGS:ACAD

US$2.6b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Deciphera Pharmaceuticals
Historique des cours de bourse
Prix actuel de l'action	US$25.59
Plus haut sur 52 semaines	US$25.61
Plus bas sur 52 semaines	US$9.90
Bêta	0.18
1Variation sur 1 mois	0.91%
Variation sur 3 mois	60.14%
Variation sur 1 an	76.48%
3Variation sur 3 ans	-28.68%
Variation sur 5 ans	6.71%
Évolution depuis l'introduction en bourse	44.99%

Nouvelles et mises à jour récentes

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30

Recent updates

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30

Diving Into Deciphera Pharmaceuticals

Apr 26

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10

Rendement pour les actionnaires

	DCPH	US Biotechs	US Marché
7D	0.08%	-2.8%	0.7%
1Y	76.5%	19.3%	32.3%

Rendement vs Industrie: DCPH a dépassé le secteur US Biotechs qui a rapporté 15.7 % au cours de l'année écoulée.

Rendement vs marché: DCPH a dépassé le marché US qui a rapporté 25.6 % au cours de l'année écoulée.

Volatilité des prix

Is DCPH's price volatile compared to industry and market?
DCPH volatility
DCPH Average Weekly Movement	20.9%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

Cours de l'action stable: Le cours de l'action de DCPH a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de DCPH est passée de 12% à 21% au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2003	355	Steve Hoerter	www.deciphera.com

Deciphera Pharmaceuticals, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Deciphera Pharmaceuticals se comparent-ils à sa capitalisation boursière ?
DCPH statistiques fondamentales
Capitalisation boursière	US$2.21b
Bénéfices(TTM)	-US$190.42m
Recettes(TTM)	US$174.91m

12.7x

Ratio P/S

-11.6x

Ratio P/E

Le site DCPH est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
DCPH compte de résultat (TTM)
Recettes	US$174.91m
Coût des recettes	US$242.52m
Marge brute	-US$67.61m
Autres dépenses	US$122.80m
Les revenus	-US$190.42m

Derniers bénéfices déclarés

Mar 31, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-2.20
Marge brute	-38.66%
Marge bénéficiaire nette	-108.87%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de DCPH?

Voir les performances historiques et les comparaisons

DCPH Aperçu des actions

Récompenses

Analyse des risques

Deciphera Pharmaceuticals, Inc. Concurrents

NasdaqGM:ZLAB

US$2.3b

NasdaqGM:VCYT

US$2.6b

NasdaqGS:TWST

US$2.7b

NasdaqGS:ACAD

US$2.6b

Historique des prix et performances

Nouvelles et mises à jour récentes

Deciphera Pharmaceuticals, Inc. Files Form 15

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index

Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet

First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023)

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Recent updates

Deciphera Pharmaceuticals, Inc. Files Form 15

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index

Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet

First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023)

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Price target increased by 7.1% to US$25.38

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Diving Into Deciphera Pharmaceuticals

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus estimates of losses per share improve by 12%

Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

President recently sold US$471k worth of stock

Senior VP & Chief Commercial Officer recently sold US$224k worth of stock

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President recently sold US$259k worth of stock

Price target increased by 11% to US$24.44

Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock (Rpretinib) at the 2023 American Society of Clinical Oncology Annual Meeting

Independent Director recently bought US$152k worth of stock

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

First quarter 2023 earnings: EPS and revenues miss analyst expectations

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Executive VP recently sold US$51k worth of stock

Now 20% undervalued

Price target increased to US$21.10

Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Price target increased to US$20.25

Deciphera Pharmaceuticals, Inc. Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Deciphera Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Senior Vice President and Chief Business Officer

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022